18+

 

Number №4, 2020 - page 35-41

The results of treatment of patients with urolithiasis by Renotinex® in early postoperative period DOI: 10.29188/2222-8543-2020-13-4-35-40

For citation: Kotov S.V., Nemenov A.A., Boeva I.D. Results of the application of the herbal complex Renotinex® in patients with urolithiasis in the early postoperative period. Experimental and Clinical Urology 2020(4):35-40. https://doi.org/10.29188/2222-8543-2020-13-4-35-40
S.V. Kotov, A.A. Nemenov, I.D. Boeva
Information about authors:
  • Kotov S.V. – Dr.Sc., Head of the Department of Urology and Andrology, Russian National Research Medical University named after N.I. Pirogova, Head of the University Clinic of Urology, Russian National Research Medical University named after N.I. Pirogova, chief specialist of Medsi in the field of «Urology»; Moscow, https://doi.org/0000-0003-3764-6131
  • Nemenov A.A. – senior laboratory assistant at the Department of Urology and Andrology, Russian National Research Medical University named after N.I. Pirogova; Moscow, Russia
  • Boeva I.D. – 2nd year resident at the Department of Urology and Andrology, Russian National Research Medical University named after N.I. Pirogov; Moscow, Russia
664

Introduction. The article analyzes the results of the clinical application of the herbal complex Renotinex®, which helps to normalize the function of the urinary tract, reduce pain, remove small stones from the kidneys and reduce the risk of recurrent stone formation.

Materials and methods. At the University Clinic of Urology, Russian National Research Medical University named after N.I. Pirogov, a prospective, single-center, randomized study was carried out from November 2019 to March 2020. All patients underwent contact ureterolithotripsy. The patients were divided evenly into 2 groups: group A (n = 30) – patients receiving Renotinex® from the first day after surgery (within 1 month), and group B (n = 30) – a control group of patients not receiving specific therapy.

Results. After 1 month of continuous use of the drug, there was an increase in the percentage of calculi discharge after contact ureterolithotripsy, a decrease in the severity of pain, normalization of the temperature curve and the absence of subfebrile condition in all patients.

Conclusion. Renotinex® has a lithokinetic effect, its active ingredients contribute to the prevention of infectious and inflammatory complications of urolithiasis.

AttachmentSize
Download2.27 MB
urolithiasis, ureterolithotripsy, terpenes, Renotinex®.

Readera - Социальная платформа публикаций

Crossref makes research outputs easy to find, cite, link, and assess